Crystal structures of HIV-1 gp120 envelope glycoprotein in complex with NBD analogues that target the CD4-binding site

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Kwon, Young Do ^a   LaLonde, Judith M ^b   Yang, Yongping ^a   Elban, Mark A ^c   Sugawara, Akihiro ^c   Courter, Joel R ^c   Jones, David M ^c   Smith III, Amos B ^c   Debnath, Asim K ^d   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BRYN MAWR COLLEGE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AS I 261; AS II 37; FLUORINE; GLYCOPROTEIN GP 120; MAE II 167; MAE II 188; NBD 556; NBD 557; PHENYLALANINE; PIPERIDINE DERIVATIVE; SERINE; UNCLASSIFIED DRUG; CD4 ANTIGEN; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; N-(4-BROMOPHENYL)-N'-(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)OXALAMIDE; N-(4-CHLOROPHENYL)-N'-(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)OXALAMIDE; OXALIC ACID DERIVATIVE; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ARTICLE; CD4+ T LYMPHOCYTE; COMPLEX FORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIGAND BINDING; NONHUMAN; PROTEIN STRUCTURE; RACEMIC MIXTURE; VIRUS ENTRY; VIRUS VIRULENCE; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; X RAY CRYSTALLOGRAPHY;

ANTIGENS, CD4; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP120; HUMANS; OXALATES; PIPERIDINES; PROTEIN BINDING;

EID: 84900319832     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085940     Document Type: Article

References (40)

1. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091-1094. (Pubitemid 15227368)
2. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, et al. (1985) Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228: 593-595. (Pubitemid 15071408)
3. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888. (Pubitemid 28299385)
4. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148. (Pubitemid 26231178)
5. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767. (Pubitemid 15195924)
6. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673. (Pubitemid 26197680)
7. Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877. (Pubitemid 26154590)
8. Furuta RA, Wild CT, Weng Y, Weiss CD (1998) Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5: 276-279. (Pubitemid 28164878)
9. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, et al. (2003) Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77: 1666-1671. (Pubitemid 36113245)
10. Koshiba T, Chan DC (2003) The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 278: 7573-7579. (Pubitemid 36800765)
11. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, et al. (2003) A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17: 691-698. (Pubitemid 36521075)
12. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732. (Pubitemid 41552605)
13. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170-1172. (Pubitemid 43093663)
14. Billick E, Seibert C, Pugach P, Ketas T, Trkola A, et al. (2004) The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J Virol 78: 4134-4144. (Pubitemid 38437219)
15. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349: 41-54.
16. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, et al. (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77: 5201-5208. (Pubitemid 36460934)
17. Watson C, Jenkinson S, Kazmierski W, Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67: 1268-1282. (Pubitemid 40410427)
18. Zhao Q, Ma L, Jiang S, Lu H, Liu S, et al. (2005) Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339: 213-225. (Pubitemid 41169789)
19. Schön A, Madani N, Klein JC, Hubicki A, Ng D, et al. (2006) Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45: 10973-10980. (Pubitemid 44360167)
20. Haim H, Si Z, Madani N, Wang L, Courter JR, et al. (2009) Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 5: e1000360.
21. Madani N, Schön A, Princiotto AM, Lalonde JM, Courter JR, et al. (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16: 1689-1701.
22. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, et al. (2010) Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84: 7558-7568.
23. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, et al. (2012) Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A 109: 5663-5668.
24. LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, et al. (2012) Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem 55: 4382-4396.
25. Curreli F, Choudhury S, Pyatkin I, Zagorodnikov VP, Bulay AK, et al. (2012) Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem 55: 4764-4775.
26. LaLonde JM, Le-Khac M, Jones DM, Courter JR, Park J, et al. (2013) Structure-based design and synthesis of an HIV-1 entry inhibitor exploiting X-ray and thermodynamic characterization. ACS Med chem Lett 4: 338-343.
27. al determinants for peptide triazole dual receptor site antagonism. Proteins 81: 271-290.
28. LaLonde JM, Elban MA, Courter JR, Sugawara A, Soeta T, et al. (2011) Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Bioorg Med Chem 19: 91-101.
29. Tuzer F, Madani N, Kamanna K, Zentner I, LaLonde J, et al. (2013) HIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism. Proteins 81: 271-290.
30. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. (Pubitemid 28289647)
31. Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, et al. (2008) CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 61: 818-826. (Pubitemid 351436193)
32. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, et al. (2008) Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. J Mol Biol 382: 510-524.
33. Acharya P, Luongo TS, Louder MK, McKee K, Yang Y, et al. (2013) Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 A cocrystal structure of gp120 and M48U1. Structure 21: 1018-1029.
34. Morellato-Castillo L, Acharya P, Combes O, Michiels J, Descours A, et al. (2013) Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. J Med Chem 56: 5033-5047.
35. Muller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317: 1881-1886. (Pubitemid 47509426)
36. Hagmann WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51: 4359-4369.
37. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography, Pt A 276: 307-326. (Pubitemid 27085611)
38. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
39. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. (Pubitemid 41742764)
40. Schrödinger LLC (2012) The PyMOL Molecular Graphics System, Version 1.5.0.3.